targeted therapies

Major Channels Involved in Neuropsychiatric Disorders and Therapeutic Perspectives.

Major channels involved in neuropsychiatric disorders and therapeutic perspectives.

Front Genet. 2013; 4: 76
Imbrici P, Camerino DC, Tricarico D

Voltage-gated ion channels are important mediators of physiological functions in the central nervous system. The cyclic activation of these… Continue reading

The Metabolism of Lymphomas.

The metabolism of lymphomas.

Curr Opin Hematol. 2013 May 13;
Calvo-Vidal MN, Cerchietti L

PURPOSE OF REVIEW: Cellular to animal to human studies are shedding light on metabolic pathways that contribute to sustaining lymphomagenesis. Old players with new metabolic… Continue reading

Targeting PI3K in Cancer: Any Good News?

Targeting PI3K in Cancer: Any Good News?

Front Oncol. 2013; 3: 108
Martini M, Ciraolo E, Gulluni F, Hirsch E

The phosphatidylinositol 3-kinase (PI3K) signaling pathway regulates several cellular processes and it’s one of the most frequently deregulated pathway… Continue reading

KCNQ Channels Regulate Age-Related Memory Impairment.

KCNQ Channels Regulate Age-Related Memory Impairment.

PLoS One. 2013; 8(4): e62445
Cavaliere S, Malik BR, Hodge JJ

In humans KCNQ2/3 heteromeric channels form an M-current that acts as a brake on neuronal excitability, with mutations causing a form of… Continue reading

Update on the Treatment of Non-Small-Cell Lung Cancer: Focus on the Cost-Effectiveness of New Agents.

Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents.

Clinicoecon Outcomes Res. 2013; 5: 137-41
Vergnenègre A, Borget I, Chouaid C

The incidence of lung cancer and the cost of drug treatment have… Continue reading

Safety and Efficacy of Pralatrexate in the Treatment of Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Ther Adv Hematol. 2012 Aug; 3(4): 227-35
Marchi E, O’Connor OA

T-cell lymphomas (TCL) are a diverse and heterogeneous group of malignancies… Continue reading

Luteolin Is a Novel P90 Ribosomal S6 Kinase (RSK) Inhibitor That Suppresses Notch4 Signaling by Blocking the Activation of Y-Box Binding Protein-1 (YB-1).

Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).

Oncotarget. 2013 Feb; 4(2): 329-45
Reipas KM, Law JH, Couto N, Islam S, Li Y, Li… Continue reading

Amphetamine, Past and Present – a Pharmacological and Clinical Perspective.

Amphetamine, past and present – a pharmacological and clinical perspective.

J Psychopharmacol. 2013 Mar 28;
Heal DJ, Smith SL, Gosden J, Nutt DJ

Amphetamine was discovered over 100 years ago. Since then, it has transformed from a drug that… Continue reading

Novel Phenolic Inhibitors of Small/Intermediate-Conductance Ca(2+)-Activated K(+) Channels, KCa3.1 and KCa2.3.

Novel Phenolic Inhibitors of Small/Intermediate-Conductance Ca(2+)-Activated K(+) Channels, KCa3.1 and KCa2.3.

PLoS One. 2013; 8(3): e58614
Oliván-Viguera A, Valero MS, Murillo MD, Wulff H, García-Otín AL, Arbonés-Mainar JM, Köhler R

BACKGROUND: KCa3.1 channels are calcium/calmodulin-regulated voltage-independent K(+) channels that… Continue reading

Role of Ess1 in Growth, Morphogenetic Switching, and RNA Polymerase II Transcription in Candida Albicans.

Role of Ess1 in Growth, Morphogenetic Switching, and RNA Polymerase II Transcription in Candida albicans.

PLoS One. 2013; 8(3): e59094
Samaranayake D, Atencio D, Morse R, Wade JT, Chaturvedi V, Hanes SD

Candida albicans is a fungal pathogen that… Continue reading